Blood proteomics of menopause map to brain aging and dementia risk
Nature Medicine, 2026
Wood Alexander M., Rabin J., Caunca M., Iadipaolo A., Cornelis L., Warrier R., Walker K., Miolane N., Bot V., Wood B., Oh H., Wyss-Coray T., Pham A., Borger J., Diaz V., Paolillo E., Kramer J., Pritschet L., Taylor C., Panizzon M., Rea Reyes R., Denkinger M., Ashton N., Johnson S., Jacobs E., Saloner R., Casaletto K.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Neurology Aging Gynecology | Cross-platform Validation | Plasma |  Olink Explore 3072/384 |
Abstract
Menopause is a hallmark process in biological aging that has been implicated in later neurodegenerative risk, but the pathways underlying this connection remain unclear. Here we used blood proteomics data from several cohorts to identify biological changes associated with menopause and its links to brain aging. In n = 80 rigorously staged (STRAW+10) pre-, peri- and postmenopausal women (aged 43–58 years) with serum NULISAseq proteomics, we show that spontaneous menopause is characterized by dysregulation in inflammatory, synaptic, metabolic and Alzheimer’s disease biologic processes, which tracked more strongly with hormones than with age. Validation analyses in age-matched pre-/peri- and postmenopausal women ( n = 2,814) with plasma Olink proteomics replicated the observed proteomic shifts and revealed broader menopause-related upregulation of inflammatory and catabolic processes plus accelerated organ and cell aging, including brain aging. In four independent cohorts of older women (average age, 60.7–72.1 years; total n = 11,925), higher menopause proteomic scores associated consistently with cognitive aging and dementia risk. The molecular signatures of menopause may inform the selection of biomarkers or therapeutic targets for brain health in midlife women.